A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : dCRT / definitive chemoradiotherapy

[Related PubMed/MEDLINE]
Total Number of Papers: 92
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   dCRT  (>> Co-occurring Abbreviation)
Long Form:   definitive chemoradiotherapy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A retrospective study of definitive chemoradiotherapy in patients with resectable small cell neuroendocrine carcinoma of the esophagus. SCNEC-E
2020 Appropriate Candidates for Salvage Esophagectomy of Initially Unresectable Locally Advanced T4 Esophageal Squamous Cell Carcinoma. BSC, CR, OS
2020 Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy. CF-RT, NEC
2020 Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease. ---
2020 Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". DFS, HNSCC, HPV-OPC, OS
2020 Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma. ---
2020 Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer. DCF-RT, EC, OS
2020 Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma. CR, ESCC, OS, PR, SALV
2020 Long-term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy. CT, EGD, ER, ESCC
10  2020 Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. PFS
11  2020 Post-treatment mortality after definitive chemoradiotherapy versus resection for esophageal cancer. EC, PSM
12  2020 Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. DMFS, LN, OS, SUV
13  2020 Risk Factors of Severe Benign Cicatricial Stricture After Definitive Chemoradiation for Localized T3 Esophageal Carcinoma. cSt, ESCC, SBCS
14  2020 Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma. ESCC
15  2020 YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma. ESCC, HR, LRFS, OS, PFS
16  2019 Association of preoperative inflammation-based prognostic score with survival in patients undergoing salvage esophagectomy. CRP, GPS, SALV
17  2019 Comparison of enteral nutrition with total parenteral nutrition for patients with locally advanced unresectable esophageal cancer harboring dysphagia in definitive chemoradiotherapy. EN, ESCC, TPN
18  2019 Comparison of long-term outcomes between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma. ESCC, OS
19  2019 Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature. RRs, TMT
20  2019 FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy. ESCC
21  2019 Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer. CI, HR, OR, OS
22  2019 Myosteatosis in a systemic inflammation-dependent manner predicts favorable survival outcomes in locally advanced esophageal cancer. CI, CT, HR, LAEC, NLR, OS, PFS
23  2019 Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma. CRTS, SCC
24  2019 The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. CR, DCR, EC, ESCC, FP, NACRT, NACT, ORR, OS, pCR, PFS
25  2019 Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. nCRT, pCR, TRG
26  2019 Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes. CI, EAC, HR, IPTW, SEER
27  2018 18F-fluorodeoxyglucose positron emission tomography predicts lymph node responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma patients. CR, ESCC, MLN
28  2018 Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on CT in a single institutional retrospective study: a propensity score matching analysis. CCR, DMFS, EC, OS, PFS, SCLN
29  2018 Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus. FFR, ITT, nCRT, OS, PP, SCC
30  2018 Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. CR, DCF-R, ESCC
31  2018 Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. CRT, TMT
32  2018 High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy. ESCC, GSH, H-score, ROS, WST
33  2018 Long-term outcome after resection for recurrent oesophageal cancer. LN, OS
34  2018 Long-Term Outcome of Definitive Chemoradiotherapy and Induction Chemoradiotherapy Followed by Surgery for T4 Esophageal Cancer with Tracheobronchial Invasion. EC, iCRT-S, LN, TBI
35  2018 Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer. NSCLC, SLS
36  2018 Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society). CRTS, NSCLC, OS, PFS
37  2018 Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma. DM, LR, NC-E, NC-O, RR
38  2018 Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy. cCR, DRs, ESCC, LR
39  2018 Prognostic impact of postoperative pulmonary complications following salvage esophagectomy after definitive chemoradiotherapy. OS
40  2018 Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. EF, ESCC
41  2018 Salvage Surgery for Esophageal Cancer: How to Improve Outcomes? AL, EC, OS, SALV
42  2018 The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis. LAESCC, nCRT, pCR
43  2018 The current status of multimodality treatment for unresectable locally advanced esophageal squamous cell carcinoma. 5-FU, EGFR, ESCC
44  2018 The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma. CIs, ESCC, ORs, OS
45  2018 TRIANgLE study (JCOG1510): A phase III study of tri-modality combination therapy with induction docetaxel (DOC), cisplatin (CDDP), 5-fluorouracil (FU) (DCF) vs definitive chemoradiotherapy (dCRT) for locally advanced unresectable squamous cell carcinoma (SCC) of the thoracic esophagus. DOC, FU, SCC
46  2018 Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma. CR, ESCC, SPM
47  2018 Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy. HR
48  2018 [A Case of Esophageal Cancer with Cervical Lymph Node Recurrence Six Years after Complete Response to Definitive Chemoradiotherapy]. ---
49  2018 [The Efficacy of Definitive Chemoradiotherapy for Thoracic Esophageal Cancer on the Point of View Salvage Surgery]. C-surgery, S-surgery
50  2017 Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent. EC, SCLN, UICC
51  2017 Definitive chemoradiotherapy. SCC
52  2017 Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer. CCT, ESCC
53  2017 Eight cases of salvage pulmonary resection for residual disease or isolated local recurrence detected after definitive chemoradiotherapy for N2 Stage-IIIA lung cancer. ---
54  2017 Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. HR, OS, PFS
55  2017 Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. ESCC, NLR, OS, PFS
56  2017 Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer. DMFS, FDG-PET, HR, NPFS, OS
57  2017 Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. EC, IC, PET, PFS, RPA
58  2017 Salvage photodynamic therapy accompanied by extended lymphadenectomy for advanced esophageal carcinoma: A case report. ---
59  2017 The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy. dNLR, DPFS, LPFSi, LPFSo, OS, PFS
60  2017 Weekly carboplatin/paclitaxel (CP) based definitive chemoradiotherapy (dCRT) for patients with inoperable oesophageal cancer unsuitable for cisplatin-fluoropyrimidine based dCRT: A single centre experience. CP
61  2017 [A Case of Solitary Lymph Node Recurrence Accompanied by Metachronous Multiple Lesion after Definitive Chemoradiotherapy for Esophageal Cancer]. ---
62  2017 [Techniques for Preventing Postoperative Complication in Esophageal Salvage Surgery]. ---
63  2016 Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma. CT, ESCC, MRI, PFS, TR
64  2016 Distribution of lymph node metastases on FDG-PET/CT in inoperable or unresectable oesophageal cancer patients and the impact on target volume definition in radiation therapy. ENI, LNM
65  2016 High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. ESCC, OS, PFS
66  2016 Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. ESCC, SD
67  2016 Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1. HR, NRI
68  2016 Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer. ACA, DFS, EUS, OC, OS, pts, RT
69  2016 Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. CRT
70  2016 [A Case of Recurrent Esophageal Cancer Treated with Salvage Lymphadenectomy after Definitive Chemoradiotherapy]. CR, FP therapy, PDT
71  2015 Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy. ESCC, OS, RFS, TTE
72  2015 Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. HCT
73  2015 Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy. CR, ESCC, MDM2
74  2015 Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery? CR
75  2015 Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. OS
76  2015 ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. ---
77  2015 [Clinical Outcomes and Prognosis of Salvage Thoracoscopic Esophagectomy after Definitive Chemoradiotherapy]. ---
78  2014 Comparison of Acuros (AXB) and Anisotropic Analytical Algorithm (AAA) for dose calculation in treatment of oesophageal cancer: effects on modelling tumour control probability. AAA, AXB, DVH, GTV, MLC, MU, OAR, VMAT
79  2014 Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. HR
80  2013 A history of surgery for locally-advanced (T4) cancer of the thoracic esophagus in Japan and a personal perspective. QOL
81  2013 Clinical prognostic factors for locally advanced esophageal squamous carcinoma treated after definitive chemoradiotherapy. OS
82  2013 Murine double minute 2 and its association with chemoradioresistance of esophageal squamous cell carcinoma. ESCC, MDM2
83  2013 Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. AC, DFS, HR, OS, SCC
84  2013 [A retrospective study on salvage surgery after local failure of definitive chemoradiotherapy for esophageal carcinomas]. ---
85  2013 [Salvage esophagectomy via a laparoscopic transhiatal approach for the treatment of esophageal cancer]. LTHA
86  2012 Prognostic significance of total disease length in esophageal cancer. CI, ELNMC, EUS, HR, OC
87  2012 Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma. ---
88  2011 Changes in the management and outcome of rectal cancer over a 10-year period in Oxford. ---
89  2011 Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer. ---
90  2009 Prognostic significance of endoscopic ultrasound-defined pleural, pericardial or peritoneal fluid in oesophageal cancer. CT, EDFE, EUS, GI
91  2009 Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. CS
92  2007 Influence of socio-economic deprivation on outcomes for patients diagnosed with oesophageal cancer. IMD, SCCs